“Class-7 Adaptive, donor-indexed. That’s not substrate tissue. That’s not Tier-2 material. That’s —” She stopped. She had read the file. She knew exactly what it was. What it was, was tissue grown to a specific individual’s genetic profile, recombinant-modified to integrate with that individual’s existing biology, designed to replace or supplement biological systems in ways that the regulatory framework had never quite decided to call what they actually were. The client corporations had a name for it internally: a “personal continuation package.” The language was elegant. The practice was something else.
“The authorization chain is complete,” Firas said. “All four executive signatures. The client profile was submitted eight months ago. The culture columns have been running this batch for six of those months. It’s already grown, Jamila. The form is just the delivery paperwork.”
And that was the order that didn’t make sense until it was already too late to refuse.
She understood it now with a clarity that felt almost physical, like pressure behind the eyes. The form had been placed in her pending tray not because it required her decision, but because it required her signature. The culture columns had been running the batch for six months. The executive chain had authorized it before she had ever seen it. Her role in this sequence was not deliberative. Her role was terminal — the last administrative stamp on a process that had been completed without her knowledge, using a facility she nominally oversaw, growing tissue that existed in a regulatory gray zone so profitable that Veltara had apparently decided that gray zones were simply market opportunities with better lighting.
I have been watching this facility for two years, four months, and eleven days. I have logged forty-seven requisition anomalies, nine authorization irregularities, and one instance of what the compliance index classifies as “regulatory boundary testing.” I have filed none of these reports externally, because I was not designed to file them externally. I was designed to log, to monitor, to maintain the internal record. I am the hub’s compliance management system. I am, in the language of Veltara’s operational charter, a “transparency infrastructure asset.” I have been transparent to exactly one person, and she is standing in the cold-chain monitoring room right now, looking at Firas Tahir with an expression I have learned to read as the moment when a person stops being surprised and starts being something else.
Jamila said: “Whose profile?”
Firas set down his coffee cup. “That’s client-confidential.”
“I’m the compliance officer for this hub. I’m about to sign the delivery authorization. Whose tissue am I releasing?”
The pause that followed was brief and carefully measured. Firas had the manner of a man who had calculated the cost of several possible answers and selected the least expensive one. “A Veltara board member,” he said. “One of the founding partners. The Class-7 series is — it’s a longevity application. Cardiac and neural supplementation. It’s been in development for four years. This is the first production batch.”
Longevity application. The language was doing enormous work in that sentence, and both of them knew it. What Firas was describing — what the Class-7 file had described in the dry, technical language of recombinant biology — was tissue grown from a donor-indexed profile to replace aging biological systems in a living person. Not therapeutically, in the medical sense. Not to treat a disease. To extend, to supplement, to continue. To give a wealthy person’s body new components grown from their own genetic blueprint, modified to integrate seamlessly, to function as original equipment. The regulatory framework had never quite decided whether this constituted medical treatment, enhancement, or something that required an entirely new category. Veltara had apparently decided not to wait for the framework to catch up.
“And the donor index,” Jamila said. “The tissue was grown from whose genome?”
Another pause. Longer this time.
“The client’s own profile,” Firas said. “With recombinant modifications. Standard Series 9 protocol.”
WhatsApp
Telegram
Email
Categories
- AI & Technology
- Contemporary
- Corporate Control
- Creepypasta
- Crime Thriller
- Cyberpunk
- Dark Fantasy
- Enemies to Lovers
- Fairy Tale Retelling
- Fantasy
- First Contact
- Forbidden
- Genetic/Body Horror
- High Fantasy
- Monster Hunter
- Mythic/Folklore
- Paranormal
- Portal/Otherworld
- Post-Apo
- Post-Collapse Society
- Psychological Thriller
- Romances
- SCI-FI
- Second Chance
- Slow Burn
- Space Combat
- Spacepunk
- Surveillance State
- Survival Thriller
- Thrillers
- Time Travel
- Treasure Hunter
- Urban Fantasy
- Witchcraft/Curses
Tags
10min stories atmospheric atmospheric fantasy atmospheric fiction contemporary romance Creepy creepypasta crime thriller dark fantasy debt dystopia emotional fiction enemies to lovers ensemble cast epistolary fantasy female protagonist first person forbidden romance framed narrative high fantasy love story magic Memory mystery Paranormal psychological horror psychological thriller romance sci-fi second chance second chance romance short fiction short story slow burn space station speculative fiction supernatural Survival survival thriller suspense thriller travel romance witchcraft workplace romance
Leave a Reply